Lisata Therapeutics, INC. 10-Q Filing

Ticker: LSTA · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 320017

Sentiment: neutral

Filing Stats: 4,660 words · 19 min read · ~16 pages · Grade level 17.9 · Accepted 2025-08-07 16:13:47

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I- FINANCIAL INFORMATION Page No. Item 1.

Financial Statements

Financial Statements: 5 Consolidated Balance Sheets at June 30 2025 (unaudited) and December 31, 2024 5 Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited) 6 Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (unaudited) 7 Consolidated Statements of Equity for the three and six months ended June 30, 2025 and 2024 (unaudited) 8 Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 10 Notes to Unaudited Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36

- OTHER INFORMATION

PART II- OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 38

Signatures

Signatures 39 4 Index

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share data) June 30, 2025 December 31, 2024 ASSETS (Unaudited) Cash and cash equivalents $ 16,835 $ 16,209 Marketable securities 5,135 15,036 Accounts receivable 501 900 Prepaid and other current assets 2,414 2,433 Total current assets 24,885 34,578 Property and equipment, net 48 72 Acquired license - intangible, net 157 192 Other assets 70 160 Total assets $ 25,160 $ 35,002 LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Liabilities Accounts payable $ 782 $ 1,284 Accrued liabilities 3,531 4,329 Total current liabilities 4,313 5,613 Other long-term liabilities 72 72 Total liabilities 4,385 5,685 Commitments and Contingencies (Note 14) Stockholders' Equity Common stock, $ 0.001 par value, authorized 500,000,000 shares; issued 8,627,202 and 8,409,582 shares at June 30, 2025 and December 31, 2024, respectively; and outstanding, 8,626,464 and 8,408,844 shares at June 30, 2025 and December 31, 2024, respectively 9 8 Additional paid-in capital 579,227 578,418 Treasury stock, at cost; 738 shares at June 30, 2025 and December 31, 2024 ( 708 ) ( 708 ) Accumulated deficit ( 557,449 ) ( 548,066 ) Accumulated other comprehensive loss ( 50 ) ( 81 ) Total Lisata Therapeutics, Inc. stockholders' equity 21,029 29,571 Non-controlling interests ( 254 ) ( 254 ) Total equity 20,775 29,317 Total liabilities, non-controlling interests and stockholders' equity $ 25,160 $ 35,002 See accompanying notes to consolidated financial statements. 5 Index LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 70 $ — $ 70 $ — Operating Expenses: Research and development 2,253 2,601 4,856 5,842 General and administrative 2,685 2,922 5,930 6,282

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing